Printer Friendly

Cape Town Consensus Report Published to Drive a 'Revolution' in the Diagnosis and Treatment of Obsessive Compulsive Disorder.

LONDON, May 29 /PRNewswire/ --

- Improved Diagnosis and Treatment Urgently Needed in This Prevalent, Chronic and Debilitating Condition

Leading international experts in obsessive compulsive disorder (OCD) have published a new consensus report aimed at providing analysis and guidance to drive improved diagnosis and management of OCD worldwide. Presented at The European Congress of Psychiatry, Madrid, 17-21 March 2007 and recently published in CNS Spectrums, the report has made a number of important recommendations including the removal of OCD from anxiety disorders to create its own category.

"While understanding about OCD has improved greatly in the last 25 years, it still remains significantly under-diagnosed and consequently, patients aren't benefiting from the major advances in treatment," says Professor Joseph Zohar, member of The Cape Town Consensus Group (CTCG) and President of the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). "It became increasingly clear that it was necessary to review the current approach to OCD, since substantial clinical and biological evidence distinguishes it from anxiety disorders. Recognition of this could lead to improvements in the diagnosis and management of this debilitating condition."

Prevalence and diagnosis of OCD

OCD affects between 2-3% of the general population(1) and takes a great toll on sufferers and their friends and families, even if they only experience symptoms for a short time each day.(2) Listed amongst the top 10 most debilitating illnesses by the World Health Organisation (WHO) in terms of loss of income and decreased quality of life,(3) OCD is associated with significant functional disability and economic costs.(4) As well, up to two-thirds of individuals with OCD also suffer from depression at some point during their illness.(5)

Despite this, it takes on average nine years to be diagnosed and 17 years from the time OCD begins for people to obtain appropriate treatment.(6) Further, only a minority of patients fully recover from the disorder.(7)

Evaluating the classification of OCD

The CTCG was brought together by the ICOCS and an unrestricted educational grant from H. Lundbeck A/S in order to analyse the clinical and scientific evidence that exists in OCD.

Current classification systems such as the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) and the International Classification of Diseases (ICD) differ in the classification of OCD and given the current development of the 5th edition of the DSM, the group felt it was important to weigh up the evidence to provide definitive guidance on the most appropriate classification and harmonise current guidelines.

OCD and anxiety disorders - key differentiators:

The CTCG consensus is based on a review of the epidemiology, neurobiology, symptomatology and etiology of OCD. This analysis highlighted a number of areas that separate OCD from anxiety disorders including:

- Its potential onset during puberty whereas other anxiety disorders have a later age of onset(8)

- Its equal prevalence amongst men and women as opposed to depressive and anxiety disorders which are more common in women(8)

- The difference in brain circuitry that mediates OCD compared to that involved in fear, stress-related or mood disorders(8)

- Its uniquely specific response to serotonin reuptake inhibitors, while noradrenergic medications (effective in anxiety and mood) are largely ineffective(8)

- The increasing evidence for treatment augmentation with second-generation antipsychotics, suggesting an important role of dopamine in OCD (which is not seen in other anxiety disorders)(8)

- Its lack of treatment response to benzodiazepines which can be affective in anxiety disorders(8)

Current treatment of OCD

There are two treatments that have been proven to be effective against OCD. They include cognitive behaviour therapy (CBT) and medication, primarily through selective serotonin reuptake inhibitors (SSRIs). SSRIs have proven to be beneficial as it appears that potent effects on brain serotonin are necessary to produce improvement in OCD.(9) The CTCG also highlights that growing evidence of the role of dopamine in OCD, pointing to the potential for the use of second generation antipsychotics within the treatment pathway.

A future definition of OCD?

Two potential methods were put forward by the CTCG to categorise OCD, one placing OCD within a broad spectrum of affective spectrum disorders and another presenting OCD as a group of disorders lying midway between affective disorders and addiction disorders.(9) Both recommendations recognise that there are actually a range of OCD subtypes which are currently classified within the umbrella of 'OCD'. These subtypes can be classified based on clinical symptoms (i.e. OCD combined with tics or hoarding), by treatment response and family studies.

Although reclassifying OCD as a distinct group of disorders may complicate the diagnostic process and fragment the concept of anxiety, the CTCG strongly recommends this approach as the proposed classification is a better fit with clinical evidence and may improve the management of OCD by moving towards treatment tailored to specific subtypes of OCD.

"Recognising the complex and varied presentation of OCD will enable the tailoring of treatment according to the specific profile of the individual patient and therefore could contribute to better treatment outcomes," says Naomi Fineberg, Consultant Psychiatrist and Honorary Senior Lecturer, Imperial College London and University of Hertfordshire. " OCD is a chronic condition requiring long-term treatment and if we can move towards management of OCD in this way we stand a much better chance of treatment success and relapse prevention to enable patients to better function in their everyday lives."

About The Cape Town Consensus Group

The Cape Town Consensus Group is a group of 14 leading experts with specific experience and long-term interested in OCD. Ten countries from four continents were represented in the group's two-day consensus meeting in Cape Town on 27-28 February 2006 to develop a consensus statement on the present and future of OCD. The members of the group include: Joseph Zohar, MD, Israel; Eric Hollander, MD, USA; Dan J. Stein, MD, PhD, South Africa; Herman G.M. Westenberg, PhD, The Netherlands; David S. Baldwin, DM, FRCPsych, UK; Borwin Bandelow, MD, Germany; Donald W. Black, MD, USA; Pierre Blier, MD, PhD, Canada; Naomi A. Fineberg, MRCPsych, UK; Martine F. Flament, MD, PhD, Canada; Dan Geller, MD, USA; Sumant Khanna, MD, PhD, India; Juan J. Lopez-Ibor, MD, Spain; and Stefano Pallanti, MD, PhD, Italy.

About the ICOCS

The International College of Obsessive Compulsive Spectrum Disorders (ICOCS) is primarily aimed at advancing, promoting and facilitating research into the causes and consequences of obsessive compulsive disorder and obsessive compulsive spectrum disorders. The organisation intends to aid and stimulate mental health professionals and others to develop research projects in this field, and to help coordinate research efforts amongst members.

The ICOCS also intends to increase public health awareness in regard to OCD and OC spectrum disorders with the hope of improving diagnosis and encouraging better deployment of resources for assessment and treatment. For more information on the ICOCS, please visit

About H. Lundbeck A/S

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally.

For further information, please visit


(1). Stein, DJ et al. "The Cape Town Consensus Statement," Poster presented at the International Anxiety Disorders Conference (IACD), Cape Town, South Africa, February 2006.

(2). OCD Question & Answers. Obsessive Compulsive Foundation. Last accessed on 22.03.07 from

(3). OCD UK intro. OCD UK. Last accessed on 22.03.07 from

(4). Stein, DJ et al. Escitalopram in the treatment of obsessive-compulsive disorder. Poster presented at the 159th Annual Meeting American Psychiatric Association, May 2006, Toronto

(5). Fineberg, NA et al. Depression within OCD: from neurobiology and clinical responses toward endophenotypes. University of Hertfordshire, Hatfield, UK. Form 7

(6). About OCD. Obsessive Compulsive Foundation. Last accessed on 21.03.07 from

(7). Stein, DJ. Obsessive-compulsive disorder. Lancet. 2002; 360(9330): 397-405

(8). Zohar, J on behalf of The Cape Town Consensus Group. Consensus Statement. From Obsessive-Compulsive Spectrum to Obsessive-Compulsive Disorders: The Cape Town Consensus Statement. CNS Spectr. 12:2(Suppl 3):59-64

(9). Hollander, E et al. Obsessive Compulsive Disorder and Obsessive Compulsive Spectrum Disorders: Diagnostic and Dimensional Issues. From Obsessive-Compulsive Spectrum to Obsessive-Compulsive Disorders: The Cape Town Consensus Statement. CNS Spectr. 12:2(Suppl 3):5-13

Media contacts: For more information, or to arrange a telephone interview with a representative from the ICOCS, please contact: Paul Gittins, Ruder Finn UK Ltd, Tel: +44-207-462-8922, Mobile: +44-7958-533-462, Email :
COPYRIGHT 2007 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:May 29, 2007
Previous Article:Mobixie Launches Free User-Generated Content for Mobiles.
Next Article:Shire plc: Block Listing Six Monthly Return.

Related Articles
Intense CBT helps treatment-refractory OCD: pediatric patients in University of Florida program saw dramatic improvements in short periods.
Compulsive hoarders reveal comorbidities: a study of 75 self-reported hoarders showed fewer axis II diagnoses than were expected.
Compulsive hoarding found common in GAD.
Data Presented Indicates Escitalopram may be a Promising Future Treatment Option in Obsessive Compulsive Disorder.
Data Presented Indicates Escitalopram may be a Promising Future Treatment Option in Obsessive Compulsive Disorder.
Health concerns common in anxiety disorders.
Cape Town Consensus Report Published to Drive a 'Revolution' in the Diagnosis and Treatment of Obsessive Compulsive Disorder.
Neurosurgeon suggests treatment for anxiety disorders.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters